AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

04 سبتمبر 2025 04:00:01 بحسب Nasdaq GlobeNewswire

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

04 أغسطس 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

31 يوليو 2025 03:30:23 بحسب Nasdaq GlobeNewswire

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

14 يوليو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios Appoints Dr. Jay Backstrom to Board of Directors

08 يوليو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

28 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

14 مايو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

09 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

02 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

01 مايو 2025 03:30:00 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

17 أبريل 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

05 مارس 2025 14:52:45 بحسب Nasdaq GlobeNewswire

Agios to Present at Upcoming Investor Conferences

04 مارس 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

20 فبراير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

13 فبراير 2025 03:31:00 بحسب Nasdaq GlobeNewswire

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

13 فبراير 2025 03:30:00 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

06 فبراير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

13 يناير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

08 يناير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

03 يناير 2025 04:00:00 بحسب Nasdaq GlobeNewswire